Merck & Co Inc (MRK)

62.53
0.21 0.34
NYSE : Health Care
Prev Close 62.32
Open 62.48
Day Low/High 62.18 / 62.99
52 Wk Low/High 47.97 / 64.00
Volume 3.70M
Avg Volume 10.03M
Exchange NYSE
Shares Outstanding 2.77B
Market Cap 173.46B
EPS 1.60
P/E Ratio 34.47
Div & Yield 1.84 (2.90%)

Latest News

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Initiating a Position in a Biotech Name

Don't be surprised; we view Bristol-Myers as "down, not out."

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

How Will Merck (MRK) Stock React to Potential Medivation Bid?

How Will Merck (MRK) Stock React to Potential Medivation Bid?

Merck (MRK), along with at least four other pharmaceuticals companies, has reportedly shown interest in acquiring Medivation (MDVN).

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Don't Write Off Bristol-Myers After Opdivo Setback

Don't Write Off Bristol-Myers After Opdivo Setback

BMY is unlikely to stay in the low $60s for long.

Results From Merck's Phase 3 Study Evaluating ZEPATIER™ (elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C Receiving Treatment For Opioid Dependence Published In Annals Of Internal Medicine

Results From Merck's Phase 3 Study Evaluating ZEPATIER™ (elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C Receiving Treatment For Opioid Dependence Published In Annals Of Internal Medicine

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR.

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

The Ironic Chess Game of Bristol-Myers

The Ironic Chess Game of Bristol-Myers

The failed trial is among the biggest single blows by a major pharma player.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

Trending Tickers: CHK, MUR, MRO, BMY

Trending Tickers: CHK, MUR, MRO, BMY

Rising crude prices help buoy a host of oil companies Monday.

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.

Health Care Drags Stocks Away From Records

Health Care Drags Stocks Away From Records

Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.

Merck Gets a Big Shot in the Arm

Merck Gets a Big Shot in the Arm

One day does not make a trend, but one day can certainly reinforce an existing trend.

Merck (MRK) Stock Upgraded at Credit Suisse

Merck (MRK) Stock Upgraded at Credit Suisse

Merck (MRK) stock was upgraded to 'outperform' at Credit Suisse after Bristol-Myers's (BMY) non-small cell lung cancer treatment missed its primary endpoint.

4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid

4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Morning Movers: MFRM, DAL, AMZN, BMY

Morning Movers: MFRM, DAL, AMZN, BMY

Mattress Firm soars on takeover bid, while Delta's worldwide computer issues are causing the stock to drop.

Analysts' Actions -- Bristol-Myers, Merck, JPMorgan, Weyerhaeuser and More

Analysts' Actions -- Bristol-Myers, Merck, JPMorgan, Weyerhaeuser and More

Here are Monday's top research calls, including downgrades for Bristol-Myers Squibb, JPMorgan and Weyerhaeuser, and an upgrade for Merck.

What Next for Bristol-Myers and Merck?

What Next for Bristol-Myers and Merck?

BMY's loss definitely looks like MRK's gain.

Takeaways, Observations and Tesla: Best of Kass

Takeaways, Observations and Tesla: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us why self-confident, glib and dogmatic is no way to go through life, son.

S&P 500, Nasdaq Score New Record Highs as Jobs Report Supports Economic Recovery

S&P 500, Nasdaq Score New Record Highs as Jobs Report Supports Economic Recovery

Stocks secure robust gains by market close Friday after the latest labor market snapshot breezes past expectations, providing solid evidence for the U.S. economic recovery.

Trending Tickers: BMY, MRK, FEYE, WING

Trending Tickers: BMY, MRK, FEYE, WING

Bristol-Myers Squibb fell sharply after its lung cancer treatment failed a clinical trial.

S&P 500 Positive for Week After July Jobs Surge

S&P 500 Positive for Week After July Jobs Surge

Stocks rally on Friday, pushing benchmark indexes into positive territory for the week, after the latest read on the labor market breezes past expectations.

Ignore Friday's Big Surprise for Bristol-Myers Squibb; It's Just Noise

Ignore Friday's Big Surprise for Bristol-Myers Squibb; It's Just Noise

Technicals show both Bristol-Myers Squibb are overbought and need corrections -- big ones.